WO1992004912A1 - Composition for inducing granulocyte production or b cell production in peripheral blood - Google Patents
Composition for inducing granulocyte production or b cell production in peripheral blood Download PDFInfo
- Publication number
- WO1992004912A1 WO1992004912A1 PCT/US1991/006850 US9106850W WO9204912A1 WO 1992004912 A1 WO1992004912 A1 WO 1992004912A1 US 9106850 W US9106850 W US 9106850W WO 9204912 A1 WO9204912 A1 WO 9204912A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tgf
- cif
- production
- peripheral blood
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to using polypeptides called cartilage-inducing factors (CIFs) and functionally related polypeptides as factors for inducing B cell proliferation in peripheral blood or granulocyte
- CIF-A chondrogenically active in vivo by itself.
- Amino acid sequencing of the CIF-A showed that it has a partial (30 amino acids) N-terminal sequence identical to that reported for a human placenta-derived polypeptide called beta-type transforming growth factor (TGF- ⁇ ).
- TGF- ⁇ beta-type transforming growth factor
- the partial N-terminal sequence of CIF-B is different from that of TGF- ⁇ .
- Both CIFs exhibit activity in the TGF- ⁇ assay (ability to induce anchorage-independent growth of normal rat kidney cell colonies in soft agar).
- TGF- ⁇ (1) promotes cell proliferation in the above mentioned soft agar culture assay and (2) promotes cell proliferation and protein deposition in a rat soft tissue wound healing model.
- the applications characterize the TGF- ⁇ s as being dimers having a molecular weight of approximately 26,000 daltons by SDS-PAGE.
- CIF-A is now referred to as TGF- ⁇ 1
- CIF-B is referred to as TGF- ⁇ 2. Disclosure of the Invention
- the present invention is based on the finding that CIFs (or TGF- ⁇ s) induce the production of B cells in peripheral blood or induce the production of
- the invention is the use of a CIF for the manufacture of a medicament for inducing
- Figure l is the amino acid sequence of platelet-derived human TGF- ⁇ monomer.
- Figure 2 is a graph of the optical densities (absorbances) (280 nm) of the gel filtration fractions of the example 1 ( C) .
- Figure 3 is a graph of the optical densities (280 nm) of eluate fractions from the preparative ion exchange chromatography of the example 1 ( D) .
- Figure 4 graphically depicts the increase in peripheral white blood cells following in vivo
- Figures 5A and 5B graphically depict the increase in peripheral B cells following in vivo
- FIGS. 6A and 6B graphically depict the increase in the percentage of both small and large B cells following in vivo administration of TGF- ⁇ 1, as reported in the example.
- polypeptides are intended to mean polypeptides, whether native or synthetic and regardless of species or derivation, that have the same amino acid sequence as the referenced polypeptide, and polypeptides of substantially homologous (i.e., at least 90% identity in amino acid sequence) but different amino acid sequence, which difference (s) does not affect biological activity (i.e., the ability to reduce B cell and granulocyte proliferation) adversely.
- CIF-A, CIF-B and TGF- ⁇ s exhibit activity in the TGF- ⁇ assay described in Methods for Preparation of
- TGF- ⁇ s by measuring the formation of cell colonies in soft agar.
- Procedures for obtaining TGF- ⁇ s from platelets, placenta and kidney tissues are described in International patent publication WO84/01106 and EPA 128,849. Briefly, they involve extracting the source material with acid-ethanol, sizing the extract by gel filtration, and isolating the TGF- ⁇ from the filtrate by high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- DMB demineralized bone
- an extractant e.g., ⁇ 4M guanidine hydrochloride, 8M urea
- CMC carboxymethyl cellulose
- proteins from the portion eluting at about 150-250 mM NaCl by RP-HPLC or gel electrophoresis are proteins from the portion eluting at about 150-250 mM NaCl by RP-HPLC or gel electrophoresis.
- CIF-A, CIF-B, and the TGF- ⁇ s isolated to date from natural sources are polypeptide dimers of
- Platelet/placenta/kidney-derived TGF- ⁇ and CIF-A and CIF-B are non-species specific as regards TGF- ⁇ activity. It is believed, therefore, that these polypeptides have been highly conserved among animal species (i.e., a given polypeptide from different mammalian species has an amino acid sequence that varies, if at all, in one or more amino acid residue additives,
- CIF-A, CIF-B, and the TGF- ⁇ s may be derived from cells or tissue of diverse animal origin or may be obtained by recombinant DNA technology.
- CIF (TGF- ⁇ ) from one vertebrate species may be used to treat another vertebrate species.
- the most common usage of CIF (TGF- ⁇ ) as an anti-inflammatory agent will be in the treatment of humans, domestic animals such as cattle, sheep, and pigs, and sports or pet animals such as dogs, cats, and horses.
- CIF-A and CIF-B are preferred for use in the invention method. Examples
- Bovine metatarsal bone was obtained fresh from a slaughterhouse and transported on dry ice.
- the bones were cleaned of marrow and non-bone tissues, broken in fragments smaller than 1 cm diameter, and pulverized in a mill at 4°C.
- the pulverized bone was washed twice with 9.4 liters of double distilled water per Kg of bone for about 15 min each, and then washed overnight in 0.01 N HCl at 4°C. Washed bone was defatted using 3 X3 volumes ethanol, followed by 3 X 3 volumes diethylether, each washed for 20 min and all at room temperature.
- the resulting defatted bone powder was then demineralized in 0.5 N HCl (25 L/Kg defatted bone) at 4°C.
- the acid was decanted and the resulting DMB washed until the wash pH was greater than 4, and the DMB dried on a suction filter.
- the DMB as prepared in A was extracted with 3.3 L of 4 M guanidine-HCl, 10 mM ethylenediamine- tetraacetic acid (EDTA), pH 6.8, 1 mM PMSF, 10 mM NEM per Kg for 16 hr, the suspension suction filtered and the non-soluble material extracted again for 4 hr.
- the soluble fractions were combined and concentrated at least 5-fold by ultrafiltration using an Amicon ultrafiltration (10K) unit, and the concentrate dialyzed against 6 changes of 35 volumes cold deionized water over a period of 4 days, and then lyophilized. All of the procedures of this paragraph were conducted at 4°C except the lyophilization which was conducted under standard
- CM-2 and CM-3 from ⁇ D were each dissolved in 0.1% trifluoroacetic acid (TFA) and aliquots of the solutions loaded onto a Vydac ® C18 RP-HPLC columns (4.6 mm ID X 25 cm) and washed with 0.1% TFA for 5 min at 1 mL/min.
- the eluting solvent was a 0%-60% acetonitrile gradient in 0.1% TFA at a rate of 2%/min.
- the proteins were stored in 0.1% TFA/acetonitrile eluting solution at -20°C until used.
- Table 1 below gives the partial amino acid compositions of CIF-A and CIF-B.
- N-terminal amino acid sequence of CIF-A is identical to that reported for platelet-derived human TGF- ⁇ (see
- TGF- ⁇ 1 (CIF-A) was purified from bovine bone and concentrated in 45% EtOH, 11 mM HCl to a
- TGF- ⁇ 1 concentration of about 5000 ⁇ g/mL, and stored at -20°C until required. The TGF- ⁇ 1 was then diluted in PBS (0.1%
- MSA MSA to a concentration of 125 ⁇ g/mL, 1% EtOH, neutral pH.
- mice Male C57B1/6 mice were treated daily for 14 days with TGF- ⁇ 1 (25 ⁇ g, 0.2 mL, subcutaneous). Control mice were given vehicle containing no TGF- ⁇ 1. The mice were evaluated 24 hours following the last treatment for histologic assessment of spleen and bone marrow,
- B-cells were typed using MAb B220 (ATCC No. TIB 164).
- Granulocytes were typed using MAb 8C5, supplied by Dr. R.L. Coffman (DNAX Research Institute, Palo Alto, CA).
- T H cells were typed using anti-CD4 MAbs, and T C/S cells using anti-CD8, both obtained from Becton- Dickinson. Propidium iodide stain was used to determine the percentage of non-viable cells.
- Figure 5A depicts the FACS analysis of the control
- Figure 5B depicts the FACS analysis of the TGF- ⁇ 1 treated sample.
- the percentage of granulocytes (8C5 + ) decreased, but the decrease in proportion was largely due to the increase in B-cells rather than a decrease in the absolute number of granulocytes.
- Size analysis (forward light scatter) of B220 + indicated that there was an increase in the percentage of both small and large B-cells (i.e., B220 + ).
- Figure 6A depicts size analysis of the control
- Figure 6B depicts size analysis of the TGF- ⁇ 1 treated sample.
- TGF- ⁇ 1 increased the number of peripheral blood B-cells. Accordingly, formulations of TGF- ⁇ are useful for treating indications associated with depressed B-cell counts or humoral immunity, such as irradiated bone marrow recipients, patients receiving chemotherapy, and congenital disorders of B-cell growth or function.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58636390A | 1990-09-21 | 1990-09-21 | |
US586,363 | 1990-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992004912A1 true WO1992004912A1 (en) | 1992-04-02 |
Family
ID=24345443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/006850 WO1992004912A1 (en) | 1990-09-21 | 1991-09-20 | Composition for inducing granulocyte production or b cell production in peripheral blood |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0502171A4 (en) |
JP (1) | JP2625033B2 (en) |
AU (1) | AU645619B2 (en) |
CA (1) | CA2067498C (en) |
WO (1) | WO1992004912A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806523A (en) * | 1985-08-06 | 1989-02-21 | Collagen Corporation | Method of treating inflammation |
US4971952A (en) * | 1986-03-06 | 1990-11-20 | Collagen Corporation | Method of treating inflammation with cartilage inducing factor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5147799A (en) * | 1990-04-25 | 1992-09-15 | Isia Bursuker | Repopulation of macrophages and granulocytes using transforming growth factor-beta |
-
1991
- 1991-09-20 AU AU86379/91A patent/AU645619B2/en not_active Ceased
- 1991-09-20 EP EP19910917641 patent/EP0502171A4/en not_active Withdrawn
- 1991-09-20 WO PCT/US1991/006850 patent/WO1992004912A1/en not_active Application Discontinuation
- 1991-09-20 JP JP3516073A patent/JP2625033B2/en not_active Expired - Lifetime
- 1991-09-20 CA CA002067498A patent/CA2067498C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806523A (en) * | 1985-08-06 | 1989-02-21 | Collagen Corporation | Method of treating inflammation |
US4971952A (en) * | 1986-03-06 | 1990-11-20 | Collagen Corporation | Method of treating inflammation with cartilage inducing factor |
Non-Patent Citations (2)
Title |
---|
See also references of EP0502171A4 * |
The Journal of Immunology, Volume 137, No. 12, issued 15 December 1986, KEHRL et al., "Transforming Growth Factor B is an Important Immuno-modulatory protein for Human B Lymphocytes", pages 3855-3860, see the entire document. * |
Also Published As
Publication number | Publication date |
---|---|
EP0502171A4 (en) | 1993-12-01 |
EP0502171A1 (en) | 1992-09-09 |
JPH05502244A (en) | 1993-04-22 |
AU645619B2 (en) | 1994-01-20 |
AU8637991A (en) | 1992-04-15 |
CA2067498A1 (en) | 1992-03-22 |
CA2067498C (en) | 1996-10-15 |
JP2625033B2 (en) | 1997-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0213776B1 (en) | Use of a cartilage-inducing factor (cif) for the manufacture of a medicament for treating inflammation | |
CA2000498C (en) | Osteogenic factors | |
US5371191A (en) | Osteoinductive protein mixtures and purification processes | |
EP0128849B1 (en) | Purified transforming growth factor-beta derived from human platelets and placentas | |
EP1428883A1 (en) | Megakaryocyte stimulating factors | |
WO1991003254A1 (en) | Wound healing | |
JPH0653674B2 (en) | Wound healing | |
JPH1070989A (en) | New osteogenesis-inductive composition | |
EP0500773B1 (en) | Non-glycosylated fgf-4 and compositions containing the same | |
US4971952A (en) | Method of treating inflammation with cartilage inducing factor | |
JPH01501361A (en) | Production of new T cell suppressor factors and their uses | |
EP0728142A1 (en) | Novel antler-derived bone growth factors | |
CA2067498C (en) | Composition for inducing granulocyte production or b cell production in peripheral blood | |
JP2004528279A (en) | Isolation of purified TGF-1 and TGF-2 from bone tissue | |
EP0626451A2 (en) | Heterodimers of a TGF-beta superfamily | |
US5391706A (en) | Purification of GM-CSF | |
EP0299746B1 (en) | Purification of gm-csf | |
US5529982A (en) | Inducing granulocyte production or B cell production in peripheral blood by TGF-β | |
JP2001524801A (en) | Secreted proteins and polynucleotides encoding them | |
EP0570478A1 (en) | Mb-40 peptide that enhances the production of interleukin-1 and modulates age-associated immune response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2067498 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991917641 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/8-8/8,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8 |
|
WWP | Wipo information: published in national office |
Ref document number: 1991917641 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1991917641 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: CA Ref document number: 2067498 Kind code of ref document: A Format of ref document f/p: F |